Loading...

Please wait

पॉडकास्ट

लोड हो रहा है...

OndaCast© 2026 OndaCast. सर्वाधिकार सुरक्षित।

सहायता संपर्क शर्तें गोपनीयता कॉपीराइट डीएमसीए बारे में रेडियो गाइड प्लेयर एम्बेड करें

Waves Explore Library Vibes Podcasts Audiobooks

पॉडकास्ट

पॉडकास्ट पर वापस जाएं

The IMID Forum

पॉडकास्ट शोपॉडकास्टen

The IMID Forum

द्वाराThe Immune-Mediated Inflammatory Disease Forum

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered a retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab

386 एपिसोड•0 सदस्य•0 कुल सुनने वाले

एपिसोड प्लेलिस्ट

50 एपिसोड

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

Dec 18, 2024•—

Discussing RA: Insights into Filgotinib and Tofacitinib in RA

Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy

Jan 22, 2025•—

Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR T-cell therapy

Author Interview: Professor Denis McGonagle, 2025

Feb 5, 2025•—

Author Interview: Professor Denis McGonagle, 2025

Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis

Feb 26, 2025•—

Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis

Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2

Feb 26, 2025•—

Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-AGILE & BE-MOBILE 1/2

Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

Mar 5, 2025•—

Discussing PsA: Bimekizumab improves patient-reported outcomes and work productivity

Author Interview: Professor Phillip Helliwell, 2025

Mar 12, 2025•—

Author Interview: Professor Phillip Helliwell, 2025

Author Interview: Professor Phillip Helliwell, March 2025

Mar 19, 2025•—

Author Interview: Professor Phillip Helliwell, March 2025

Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs

Mar 26, 2025•—

Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive first-line DMARDs

Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA

Apr 2, 2025•—

Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsDMARD failure in PsA

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA

Apr 16, 2025•—

Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progression in SpA

Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis

May 1, 2025•—

Discussing RA: MACE, VTE, and malignancy in filgotinib RA and UC patients, and MACE related to JAKis

Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA

May 8, 2025•—

Discussing axSpA: JAKi cycling and long-term safety of bimekizumab in patients with axSpA or PsA

Author Interview: Dr Saqr Alsakarneh, May 2025

May 22, 2025•—

Author Interview: Dr Saqr Alsakarneh, May 2025

Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs

May 28, 2025•—

Webinar Highlights Podcast: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs

Podcast: AuToDeCRA, June 2025

Jun 4, 2025•—

Podcast: AuToDeCRA, June 2025

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

Jun 5, 2025•—

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

EULAR 2025 Preview Podcast

Jun 9, 2025•—

EULAR 2025 Preview Podcast

EULAR 2025 Highlights: Day 1

Jun 11, 2025•—

EULAR 2025 Highlights: Day 1

EULAR 2025 Highlights: Day 2

Jun 12, 2025•—

EULAR 2025 Highlights: Day 2

Discussing PsA: Real-world data on biologic switching and the development of EMMs

Jun 12, 2025•—

Discussing PsA: Real-world data on biologic switching and the development of EMMs

EULAR 2025 Highlights: Day 3

Jun 13, 2025•—

EULAR 2025 Highlights: Day 3

EULAR 2025 Highlights: Day 4

Jun 14, 2025•—

EULAR 2025 Highlights: Day 4

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

Jun 26, 2025•—

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

EULAR 2025 Review Podcast

Jul 2, 2025•—

EULAR 2025 Review Podcast

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

Jul 3, 2025•—

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Jul 10, 2025•—

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Jul 31, 2025•—

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Aug 7, 2025•—

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Aug 14, 2025•—

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Aug 28, 2025•—

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Sep 4, 2025•—

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Sep 18, 2025•—

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Sep 25, 2025•—

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Author Interview: Doctor David Kellner, September 2025

Oct 2, 2025•—

Author Interview: Doctor David Kellner, September 2025

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

Oct 9, 2025•—

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

ACR 2025 Preview Podcast

Oct 22, 2025•—

ACR 2025 Preview Podcast

ACR Daily Highlights: Day 1

Oct 26, 2025•—

ACR Daily Highlights: Day 1

ACR Daily Highlights: Day 2

Oct 27, 2025•—

ACR Daily Highlights: Day 2

Pathways Modulating IMIDs: Webinar Highlights Podcast

Oct 28, 2025•—

Pathways Modulating IMIDs: Webinar Highlights Podcast

ACR Daily Highlights: Day 3

Oct 28, 2025•—

ACR Daily Highlights: Day 3

ACR Daily Highlights Day 4

Oct 29, 2025•—

ACR Daily Highlights Day 4

ACR 2025 Review Podcast

Nov 5, 2025•—

ACR 2025 Review Podcast

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

Nov 6, 2025•—

Discussing RA: Long-term management of elderly patients with RA treated with tocilizumab

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Nov 13, 2025•—

Discussing axSpA: Adalimumab dosing and uveitis recurrence in patients with ankylosing spondylitis

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Nov 16, 2025•—

Webinar Highlights: Advancing Patient Care Through an Interdisciplinary Approach to IMIDs: Part 2

Author Interview: Professor Filip Rob, 2025

Nov 20, 2025•—

Author Interview: Professor Filip Rob, 2025

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Nov 27, 2025•—

Discussing RA: Real-world evaluation of JAKi efficacy, persistence, and cardiovascular safety in RA

Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Dec 4, 2025•—

Discussing PsA: Uveitis risk and treatment sequencing outcomes in axSpa and PsA

Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab

Dec 11, 2025•—

Discussing axSpA: Real-world outcomes for patients with axSpA receiving SC infliximab

आपको ये भी पसंद आ सकते हैं

OndaCast© 2026 OndaCast. सर्वाधिकार सुरक्षित।

सहायता संपर्क शर्तें गोपनीयता कॉपीराइट डीएमसीए बारे में रेडियो गाइड प्लेयर एम्बेड करें

Waves Explore Library Vibes Podcasts Audiobooks